Genmab A/S or Telix Pharmaceuticals Limited: Who Leads in Yearly Revenue?

Genmab A/S dominates Telix in revenue growth over the past decade.

__timestamp	Genmab A/S	Telix Pharmaceuticals Limited
Wednesday, January 1, 2014	850385000	28336824
Thursday, January 1, 2015	1133041000	32319194
Friday, January 1, 2016	1816122000	29404631
Sunday, January 1, 2017	2365436000	31769230
Monday, January 1, 2018	3025137000	20439380
Tuesday, January 1, 2019	5366000000	24186536
Wednesday, January 1, 2020	10111000000	4680000
Friday, January 1, 2021	8482000000	4898000
Saturday, January 1, 2022	14595000000	155984000
Sunday, January 1, 2023	16474000000	496659000
Monday, January 1, 2024	21526000000

Unleashing insights

Genmab A/S vs. Telix Pharmaceuticals: A Revenue Showdown

In the competitive landscape of biotechnology, revenue growth is a key indicator of success. Over the past decade, Genmab A/S has consistently outperformed Telix Pharmaceuticals Limited in annual revenue. From 2014 to 2023, Genmab's revenue surged by over 1,800%, reaching a peak of approximately $16.5 billion in 2023. In contrast, Telix's revenue, while growing, remains modest, with a notable increase to nearly $500 million in the same year.

Genmab's strategic focus on innovative antibody therapeutics has propelled its financial success, while Telix, specializing in radiopharmaceuticals, is still in its growth phase. The data highlights Genmab's dominance, with its revenue in 2023 being over 33 times that of Telix. As the biotech industry evolves, these companies' financial trajectories will be crucial to watch.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025